Serum potassium levels were measured before and during electroconvulsive therapy, in patients anaesthetized with methohexitone and thiopentone. In no case was any dangerous potassium level recorded. In patients anaesthetized with methohexitone, serum potassium levels showed a significant rise following the injection of suxamethonium and an induced convulsion. Patients anaesthetized with thiopentone showed a small rise in serum potassium, which was not significant. The protective effect of thiopentone given prior to suxamethonium and electroconvulsive therapy was demonstrated. A significant rise in serum potassium from the 1st to the 4th and 7th treatment was shown in those patients anaesthetized with thiopentone. This group also showed a significant difference between the serum potassium means of schizophrenics and depressives, which formed part of a large inter-patient difference.
Serum potassium levels were measured before and during electroconvulsive therapy, in patients anaesthetized with methohexitone and thiopentone. In no case was any dangerous potassium level recorded. In patients anaesthetized with methohexitone, serum potassium levels showed a significant rise following the injection of suxamethonium and an induced convulsion. Patients anaesthetized with thiopentone showed a small rise in serum potassium, which was not significant. The protective effect of thiopentone given prior to suxamethonium and electroconvulsive therapy was demonstrated. A significant rise in serum potassium from the 1st to the 4th and 7th treatment was shown in those patients anaesthetized with thiopentone. This group also showed a significant difference between the serum potassium means of schizophrenics and depressives, which formed part of a large inter-patient difference.
Although one might expect a considerable rise in serum potassium following suxamethonium administration (Weintraub, Heisterkamp, and Cooperman, 1969; Roth and Wiithrich, 1969; Belin and Karleen, 1966; Tolmie, Joyce, and Mitchell, 1967) , and an induced convulsion, as in electroconvulsive therapy (ECT), clinical experience shows that few difficulties occur. In the electroconvulsive therapy (ECT) situation any rise in serum potassium may be modified by prior injection of thiopentone (Stevenson, 1960a) and by changes in extracellular fluid volume which occur in patients undergoing electroconvulsive therapy (ECT) and recovering from depression (Hullein et al., 1967) .
It was therefore decided to measure the immediate changes in serum potassium levels occurring during electroconvulsive therapy (ECT) in patients anaesthetized with thiopentone and to compare these changes with those occurring after methohexitone induction.
METHOD
Fifty patients, 25 (7 males, 18 females) in Leeds, and 25 (17 males, 8 females) in York, were considered and were unselected in that all new cases starting treatment on Mondays and Wednesdays in York, and on Fridays in Leeds, were included. Blood was taken during the 1st, 4th, and 7th electroconvulsive treatment in York, and the 1st, 3rd, and 5th electroconvulsive treatment in Leeds. Also, blood was taken on each occasion from 50 nonpsychiatric controls, 25 in Leeds and 25 in York. All patients continued taking their usual drugs as prescribed by their psychiatrist.
Patients were pre-medicated with atropine 0.8 mg injected subcutaneously 45 min before treatment. Care was taken to avoid exercise of the patient or his arm prior to collection of blood. Minimal occlusion of veins was used in order to prevent a rise in the serum potassium (Brown et al., 1970) . A needle (Armoven) was inserted into a vein and 5-7 ml of blood was collected (pre-induction sample). Patients in Leeds were anaesthetized with a "sleep dose" of methohexitone and patients in York with a "sleep dose" of thiopentone. Suxamethonium (30 mg for females, 40 mg for males) was then injected through the same needle, and the lungs ventilated with oxygen. Approximately 120 sec following the injection of suxamethonium, a further 5-7 ml of blood (post-induction sample) was withdrawn. The shock was given and ventilation with oxygen was continued until spontaneous respiration was restored at which stage a further sample of blood (post-shock sample) was taken. The duration of apnoea was measured.
At York laboratory serum potassium levels were estimated using a Fischer Porter automatic dilutor and an Instrumentation Laboratory flame photo- 
RESULTS
The mean serum potassium level of the non-psychiatric control group at York was significantly higher than that of the control group at Leeds ( Thiopentone group, York. There was no significant difference between the mean serum potassium level in the control group and in the 25 patients before anaesthesia (table IB) . There was no significant change in the mean values in the treatment group before anaesthesia, following induction and suxamethonium, and post shock on return of spontaneous respiration (table IC) . This absence of significant difference was verified by analysis of variance, removing as possible sources of variation the effect due to the individual patients and the effect due to order of treatment. There was a significant difference in the rising value for serum potassium between the 1st and the 4th and the 7th treatment (tables II and IE). When the differences of sex and diagnosis were considered, seven schizophrenic patients were shown to have a significantly lower serum potassium level than the depressive patients (tables IV and V; mean difference 0.23 m.equiv/1.). The maximum post-treatment serum potassium level recorded was 5.2 m.equiv/1.; the maximum change from pre-to post-treatment was +0.7 m.equiv/1. in a patient whose pre-treatment level was 4.5 m.equiv/1. and the maximum pre-treatment level was 5.4 m.equiv/1., this patient showed a fall of 0.5 m.equiv/1. following treatment.
Methohexitone group, Leeds.
The mean serum potassium level before anaesthesia in 25 patients was significantly lower than IB) . There was a significant rise following anaesthesia, suxamethonium, and shock treatment (tables IC and II). Further analysis showed that the rise in serum potassium level following induction and suxamethonium was not significant, nor was the rise in serum potassium between the post-induction and post-shock readings significant. There was no significant rise between the first and subsequent treatments in this group. There was a significant inter-patient difference (table II) (table IV) . There were only 2 schizophrenic patients in this methohexitone group, compared with 7 in the thiopentone group.
The maximum serum potassium level reached in the post-shock measurements was 5.2 m.equiv/l., the maximum change from pre-to post-treatment was + 0.8 m.equiv/l. in a patient whose pre-induction level was 3.3 m.equiv/l. and the maximum preinduction level was 5.2 m.equiv/l. This patient showed a fall of 0.6 m.equiv/l., following treatment.
DISCUSSION
It is evident from these results that the homeostatic processes regulating the serum potassium are effective in these patients, as individuals with a high initial serum potassium never show the maximum rise shown by patients with a lower initial serum potassium. In this study dangerous levels of serum potassium were never seen, and the rise that did occur was less after thiopentone than after methohexitone. It is postulated that thiopentone administration reduced the increase in serum potassium which would otherwise occur following suxamethonium and the convulsion. Possible mechanisms for this protective action of thiopentone would appear to be (1) the driving of potassium into the cells (Stevenson, 1960a) and (2) the curariform action of thiopentone increasing the dual blocking effect of suxamethonium and the convulsion.
The clinical consequence of this finding may be that thiopentone is a useful induction agent, to be used prior to suxamethonium in high-risk situations, e.g. tetanus and burns as well as electroconvulsive therapy (ECT). In this regard it is interesting to note that, in the six cases of hyperkalaemia and cardiac arrest occurring in patients reported by Roth and Wiithrich (1969) , thiopentone was not employed.
The same is true of the cardiac arrests reported in 1 burns case by Belin and Karleen (1969) , and in 4 out of 5 anaesthetics given in a burns case reported by Tolmie, Joyce, and Mitchell (1967) .
The other interesting finding from this study was the rise in serum potassium which occurred in later treatments in the York series, and which was absent from the Leeds data. The reason for this rise in serum potassium is unknown at the present time; the difference between the Leeds and York groups may be explicable by reason of the different balance of disease categories in the two series: thus, the York group contained more schizophrenics (seven) and fewer depressives than the Leeds group. It is known, however, that during recovery from depression the extracellular fluid volume expands and this tends to minimize any elevation in serum potassium level. This potassium-lowering factor would obviously be more effective in the Leeds group, with the higher proportion of depressed patients. It is also impossible to say from these results if the elevated serum potassium is due to a maintained response from treatment to treatment, or to an increased response to potassium-releasing factors in each treatment over the series. The effect of the known diurnal variation of potassium on these results has not been considered. This may, however, be relevant since the Leeds samples were collected in the early afternoon and the York samples in the morning.
Some caution must be used in interpreting results of an estimation affected by a large number of variables which are difficult to control and which show a large inter-patient difference. However, the expected rise of serum potassium following suxamethonium and electroconvulsive therapy was shown when patients were anaesthetized wizth methohexitone. Thiopentone, known to lower the serum potassium in dogs, was shown to prevent a significant rise in serum potassium in this situation. Hence, thiopentone is probably the better induction agent for patients who are to receive suxamethonium, especially those who might respond to it by an abnormal rise in serum potassium. It has also been possible to demonstrate, though not to assess fully, a rise in serum potassium following suxamethonium and electroconvulsive therapy over a course of ECT in hospital in-patients anaesthetized with thiopentone. 
RESUMEN
Fueron medidos los niveles de potasio serico antes y durante la terapia electroconvulsiva en pacientes anestesiados con metohexitona y tiopentona. En ningun caso fue registradb un nivel peligroso de potasio. En los pacientes anestesiados con metohexitona, los niveles de potasio serico mostraron una eleyacion significativa despues de la inyeccion de suxametonio y una convulsidn inducida. Las pacientes anestesiadas con tiopentona mostraron una pequefia elevacion en el potasio serico que no era significativa. Fue demostrado el efecto protector de la tiopentona administrada antes del suxametonio y de la terapia electroconvulsiva. Fue demostrada una elevacidn significativa en el potasio serico desde el 1" hasta el 4°y 7° tratamiento en los pacientes anestesiados con tiopentona. Este grupo tambien mostro una diferencia significativa entre las medias del potasio serico de pacientes esquizofrenicos y depresivos que formaba parte de una gran diferencia entre pacientes.
